Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma

Meng, Maobin; Wang, Huanhuan; Zeng, Xianliang; Zhao, Lujun; Wang, Ping; Hao, Xishan

doi:10.5582/ddt.2015.01056

Cited by 20 publications

(21 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocellular carcinoma (HCC) is one of the deadliest cancers with an increasing incidence. [1][2][3] Although different types of treatments, such as surgery, 4 radiotherapy, 5 chemotherapy, 6 ablation, 7 and liver transplantation, 8 as well as molecular targeted drugs, 9 have been used to treat HCC, the poor prognosis has seen limited improvement. 10 It is of critical importance to understand the molecular mechanisms of High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway tumorigenesis and progression in HCC because further knowledge can provide specific and sensitive diagnostic biomarkers and effective therapeutic targets for the diagnosis and treatment of HCC.…”

Section: Introductionmentioning

confidence: 99%

High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway

Zhang

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

The aim of this study was to investigate the role of G-protein signaling modulator 2 in the carcinogenesis and progression of hepatocellular carcinoma. We previously showed that G-protein signaling modulator 2 was upregulated in hepatitis B virus-related hepatocellular carcinoma tissues through a hierarchical clustering analysis. With this study, we first assessed the expression pattern of G-protein signaling modulator 2 in hepatocellular carcinoma specimens and adjacent noncancerous tissues; clinical data were analyzed, along survival times, utilizing the Kaplan-Meier method. Moreover, the functions of G-protein signaling modulator 2 were examined using small-interfering RNAs in vitro. The results showed that G-protein signaling modulator 2 was clearly overexpressed in hepatocellular carcinoma tissues and cell lines and that the G-protein signaling modulator 2 expression level was related to tumor size and hepatitis B virus infection. Furthermore, G-protein signaling modulator 2 knockdown studies suggested that G-protein signaling modulator 2 accelerates cell growth, cell cycle, migration, and invasion and inhibits apoptosis, acting as an oncogene in hepatocellular carcinoma. Western blotting indicated that silencing of G-protein signaling modulator 2 in HepG2 and SMMC-7721 cells increased the expression levels of Bax, caspase-3, and E-cadherin, while notably suppressing the cyclin-dependent kinase 4, cyclin-dependent kinase 6, CyclinD1, Snail1, Vimentin, and matrix metallopeptidase 9 expression levels, compared with that in the control groups. In addition, we found that G-protein signaling modulator 2 can affect the expression of key proteins involved in protein kinase B activation. In conclusion, high expression of G-protein signaling modulator 2 was involved in the pathological processes of hepatocellular carcinoma through activation of the phosphatidylinositol 3-kinase/protein kinase B signaling pathway, which may provide an attractive potential diagnostic biomarker and therapeutic target for treatment of hepatocellular carcinoma.

show abstract

Section: Introductionmentioning

confidence: 99%

High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway

Zhang

et al. 2017

Tumour Biol.

View full text Add to dashboard Cite

show abstract

“…Recently, growing evidences have supported that stereotactic body radiotherapy (SBRT) is a safe, non-invasive, and effective technology, showing high local control (LC) rate and low incidence of complication in selected metastatic patients, especially when surgery is not allowed or refused567. It is defined by the American Society of Radiation Oncology as external-beam radiotherapy used to precisely deliver high doses of radiation to an extracranial target within the body, either as a single dose or a small limited number of radiation fractions8.…”

mentioning

confidence: 99%

“…The therapeutic indications of CyberKnife previously included a variety of different tumors, such as lung cancer11, liver cancer7, pancreatic cancer12, and colorectal cancer13. However, very little is known about its clinical use for the treatment of ILNM.…”

mentioning

confidence: 99%

Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metastasis

Wang

Zhuang

et al. 2016

Sci Rep

Self Cite

View full text Add to dashboard Cite

The CyberKnife is a robotic stereotactic body radiotherapy (SBRT) system which has shown promising results for many malignances with good efficacy and low toxicity. This study aims to evaluate the response and local control (LC) obtained with CyberKnife in the management of iliac lymph node metastases (ILNM). Twenty-two patients with 27 ILNM were treated by CyberKnife from May 2010 to May 2016. Median follow-up time was 33 months (8–97). The complete response, partial response, stable disease and progression disease rates were 37.0%, 48.0%, 7.5% and 7.5% respectively. The 1-, 2-, and 3-year LC rates were all 90.6%, and overall survival rates were 78.8%, 60.6%, and 43.3% respectively. All patients with pelvic pain and ureter obstruction achieved good and fast symptom relief, while leg edema persisted in 2 patients. The general treatment tolerance was acceptable and no severe toxicities were reported. No factors were found correlated with local failure. While overall survival (OS) was better for patients who had received a total dose more than 30 Gy or prior systemic treatment, and whose symptoms were relieved. Taken together, CyberKnife is an effective therapeutic option for ILNM, providing high LC rate and good symptom relief with minimal toxicity.

show abstract

“…With the development of liver radiobiology and the significant progress of radiotherapy technology, SBRT has been gradually applied to HCC in the intermediate and advanced stage [11] . However, due to the relatively small sample size of related clinical trials and the lack of multi-center and large-sample randomized controlled studies, the efficacy of SBRT combined with TACE in the treatment of intermediate-and advancedstage HCC is difficult to draw definite conclusions.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of stereotactic body radiation therapy combined with transarterial chemoembolization for Chinese intermediate-to advanced-stage hepatocellular carcinoma patients: a systematic review and meta-analysis

Zhao¹,

Dai²,

Shao³

et al. 2019

View full text Add to dashboard Cite

show abstract

Stereotactic body radiation therapy: A novel treatment modality for inoperable hepatocellular carcinoma

Cited by 20 publications

References 48 publications

High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway

High expression of G-protein signaling modulator 2 in hepatocellular carcinoma facilitates tumor growth and metastasis by activating the PI3K/AKT signaling pathway

Stereotactic body radiation therapy induces fast tumor control and symptom relief in patients with iliac lymph node metastasis

Efficacy and safety of stereotactic body radiation therapy combined with transarterial chemoembolization for Chinese intermediate-to advanced-stage hepatocellular carcinoma patients: a systematic review and meta-analysis

Contact Info

Product

Resources

About